The Wuhan SARS-CoV-2-What's next for China

J Med Virol. 2020 Jun;92(6):546-547. doi: 10.1002/jmv.25738. Epub 2020 Mar 18.

Authors

Hongzhou Lu¹, Charles W Stratton², Yi-Wei Tang³

Affiliations

¹ Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
² Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Cepheid, Danaher Diagnostic Platform, Shanghai, China.

No abstract available

MeSH terms

Antiviral Agents / chemical synthesis
Antiviral Agents / therapeutic use
Betacoronavirus / drug effects
Betacoronavirus / genetics
Betacoronavirus / pathogenicity*
COVID-19
COVID-19 Vaccines
China / epidemiology
Communicable Disease Control / organization & administration*
Coronavirus Infections / diagnosis
Coronavirus Infections / epidemiology*
Coronavirus Infections / prevention & control
Coronavirus Infections / therapy
Coronavirus Infections / transmission
Disease Management
Disease Outbreaks*
Humans
Pandemics
Pneumonia, Viral / diagnosis
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / therapy
Pneumonia, Viral / transmission
SARS-CoV-2
Travel / statistics & numerical data
Viral Vaccines / biosynthesis

Substances

Antiviral Agents
COVID-19 Vaccines
Viral Vaccines